|
|
Agenix Announces Initial China Sales of Hep B Drug YouHeDing
publication date: Jan 4, 2008
Australian biotech Agenix reported that its new treatment for hepatitis B notched sales of 10 million RMB ($1.4 million) in December, its first month on the market. YouHeDing, as the treatment is known, was approved by the SFDA in October 2007. According to Agenix, YouHeDing (adefovir dipivoxil tablets) has a novel crystalline structure when compared to other approved versions of adefovir dipivoxil. It is the first triclinic structured form of the drug developed and patented in China. More details...
Stock Symbol: (ASX: AGX)
|
ChinaBio® Events
ChinaBio® Partnering Forum 2012May 23-24, 2012 Suzhou, China >>More events...
Partner Events
 China Healthcare Investment Conference 2012March 13-15, 2012 Shanghai, China Shanghai CEO ConferenceMarch 28-29, 2012 Shanghai, China >>More details...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|